Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy 2023-02-28 09:16
RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA 2022-12-13 12:30
RemeGen's Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines 2022-11-17 08:00
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients 2022-11-01 12:12
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis 2022-10-13 08:00
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China 2022-09-19 21:00
Biotech Company RemeGen Commemorates International Self-Care Day with Health Initiatives 2022-07-25 11:00
RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting 2022-05-24 10:27
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome 2022-01-26 10:52
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome 2022-01-25 09:00
RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021 2021-12-15 09:35
RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer Treatment 2021-12-03 13:45
1 2